TrialJournal for immunotherapy of cancer2026

AdvanTIG-301: a phase III study of ociperlimab plus tislelizumab and concurrent chemoradiotherapy in stage III unresectable non-small cell lung cancer.

Ligang Xing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.